Towards Healthcare
Gastrointestinal Drugs Market Expands USD 55.85 Bn by 2034

Gastrointestinal Drugs Market Opportunities and Top Key Players

Based on market forecasts, the global gastrointestinal drugs market, projected at USD 40.21 billion in 2024, is expected to reach USD 55.85 billion by 2034, growing at a CAGR of 3.34% over the forecast period. The gastrointestinal drugs market is growing due to these drugs are used for various treatments in people with excess stomach acid, stomach or intestinal ulcers, or heartburn.

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The gastrointestinal drugs market is projected to reach USD 55.85 billion by 2034, up from USD 41.55 billion in 2025, at a CAGR of 3.34%

Asia Pacific is the fastest-growing region due to rising healthcare infrastructure, increasing disposable income, and higher disease prevalence

Biologics and biosimilars are redefining treatment protocols by offering targeted therapy for chronic conditions like Crohn and UC

AI is transforming drug discovery, diagnostics, and patient stratification in gastroenterology.

Stringent FDA and EMA regulations ensure drug safety and efficacy but can delay product launches.

Drug formulation challenges such as low solubility, poor permeability, and mucosal barriers limit the bioavailability of some GI drugs

Major players include AbbVie, Pfizer, AstraZeneca, Takeda, Gilead Sciences, Biogen, and Janssen.
Any Questions